News

Roflumilast cream 0.3% is filed with Health Canada to treat plaque psoriasis

Read time: 1 mins

Published:29th Jul 2022

Arcutis Biotherapeutics, Inc. has announced that Health Canada has accepted for review the New Drug Submission (NDS) for roflumilast cream 0.3% for the treatment of plaque psoriasis in adults and adolescents

Roflumilast cream (ARQ-151) is a once-daily topical formulation of roflumilast, a highly potent and selective inhibitor of phosphodiesterase type 4 (PDE4), an enzyme that drives overactive immune responses. PDE4 is an established target in dermatology. The target action date is April 30, 2023.

Condition: Psoriasis

Type: drug

Learning Zone Homepage

Psoriasis Academy

When it comes to psoriasis, a knowledgeable healthcare professional is highly valued by patients (Pariser et al., 2016). With this in mind, we created The Psoriasis Academy, an online hub featuring succinct and easily accessible information for all healthcare professionals who want to know more about psoriasis and keep up to date with the latest developments.

Learning Zone Homepage

Improving treatment options for childhood psoriasis

This Learning Zone introduces you to our young patient Mia who, along with our paediatric psoriasis experts, helps us to describe the burden of childhood psoriasis for patients and their families, particularly the difficulties around diagnosis, comorbidities and limited treatment options.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

Positive data for V116, an investigational, 21-valent pneumococcal conjugate vaccine specifically designed for adults

Merck Inc., known as MSD outside of the United States and Canada, announced results from STRIDE-10, a Phase III trial evaluating V116, the company’s investigational, adult-specific 21-valent pneumococcal conjugate vaccine, at the 34th European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global) in Barcelona, Spain

3 mins

Drug news

Stenoparib shows clear clinical benefit and achieves significant milestone with early conclusion of phase II trial in advanced ovarian cancer

Allarity Therapeutics, Inc. announced the early discontinuation of its Phase II clinical trial of stenoparib, a novel PARP inhibitor, for the treatment of advanced recurrent ovarian cancer

2 min

Drug news

Calquence (acalabrutinib)combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial

Positive high-level results from an interim analysis of the ECHO Phase III trial showed AstraZeneca’s Calquence (acalabrutinib) in combination with standard-of-care chemoimmunotherapy, bendamustine and rituximab, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus standard of care in previously untreated adult patients with mantle cell lymphoma (MCL)

2 min

See all news